Familial hypercholesterolemia and the atherosclerotic disease

Area of Science:

• Cardiology
• Genetics
• Metabolic Disorders

Background:

• Familial hypercholesterolemia (FH) is an autosomal dominant inherited disorder.
• It leads to premature atherosclerotic cardiovascular diseases due to genetic mutations affecting LDL receptors.
• Heterozygous FH affects 1 in 500 people, causing elevated LDL-cholesterol from birth.

Purpose of the Study:

• To highlight the importance of early FH diagnosis through clinical suspicion and family history.
• To discuss current treatment guidelines recommending significant LDL-C reduction.
• To evaluate the efficacy of combination therapy for FH management.

Main Methods:

• Clinical diagnosis based on family history and physical findings (e.g., xanthomas).
• Review of current treatment guidelines for LDL-cholesterol lowering.
• Assessment of lipid-lowering therapies, including statins and ezetimibe.

Main Results:

• Statins are the primary choice for lowering LDL-C due to safety and efficacy.
• Many FH patients do not achieve ideal LDL-C levels with statin monotherapy.
• Combination therapy with ezetimibe shows promising results in further reducing LDL-C.

Conclusions:

• Early clinical suspicion is crucial for diagnosing FH.
• Achieving target LDL-C levels often requires more than monotherapy.
• Ezetimibe in combination therapy represents an effective strategy for managing FH.